Certainly, the use of estrogen-based therapies is not without controversy (Koire et al., 2022), but a greater understanding of its risks and benefits is needed, especially in the contexts of APOE genotype and obesity. This evidence concerns the gene APOE and obesity due to melanocortin 4 receptor deficiency.